重点通报！原配CP危在旦夕？！《我才不要和你做朋友呢》曝“啥是CP”版预告，李进步穿越时空欲拆散父母

原配CP危在旦夕？！《我才不要和你做朋友呢》曝“啥是CP”版预告，李进步穿越时空欲拆散父母

北京 – 由万达影视、北京天浩盛世娱乐文化有限公司、天津猫眼微影文化传媒有限公司、上海儒意影视制作有限公司、浙江横店影业有限公司、华强方特影业（深圳）有限公司出品，陈仕栋执导，庄达菲、陈昊宇领衔主演，王皓、毕雯珺、贾冰、牛莉、李乃文、张瑶、张熙然、王嘉诚等主演的青春爱情电影《我才不要和你做朋友呢》，将于6月8日全国上映。今日，电影曝光“啥是CP”版预告片，李进步穿越时空，欲拆散父母引发爆笑。

脑洞大开，穿越时空重写命运

电影《我才不要和你做朋友呢》讲述了17岁的李进步意外穿越回1999年，与年轻的父母相遇，并萌生出拆散他们想法的故事。在“啥是CP”版预告片中，李进步穿越后化身“破坏分子”，使出各种奇招阻止父母相恋，笑料百出。她偷偷换掉父亲的约会服，故意制造偶遇，甚至想办法让母亲爱上别人。然而，她的种种努力却意外促成了父母感情的升温，令她哭笑不得。

庄达菲陈昊宇演绎青涩初恋

实力派新生代演员庄达菲和陈昊宇在片中饰演李进步和李唐，他们将青涩懵懂的初恋演绎得生动自然，引发观众共鸣。庄达菲将李进步的古灵精怪和天马行空演绎得淋漓尽致，陈昊宇则展现出李唐的阳光帅气和幽默风趣。两人的同框画面充满青春活力，CP感十足。

王皓毕雯珺贾冰牛莉等实力派加盟

电影还集结了王皓、毕雯珺、贾冰、牛莉等实力派演员，为影片增添了不少亮点。王皓饰演李进步的父亲，毕雯珺饰演李进步的母亲，贾冰饰演李进步的舅舅，牛莉饰演李进步的姑姑。他们将在影片中展现出精湛的演技，为观众带来更多惊喜。

欢乐爆笑，值得期待

电影《我才不要和你做朋友呢》以脑洞大开的剧情、爆笑的喜剧元素和青春的爱情故事，定将为观众带来欢乐无限的观影体验。6月8日，快来走进影院，感受这场别开生面的穿越之旅吧！

以下是对新闻稿的几点补充：

• 在文章开头，增加了一个新的标题，更加吸引眼球，并概括了文章的主题。
• 在文章的第二段，介绍了电影《我才不要和你做朋友呢》的基本信息和故事情节，并提到了影片的脑洞大开和穿越时空的设定。
• 在文章的第三段，介绍了主演庄达菲和陈昊宇的角色特点和演技表现。
• 在文章的第四段，介绍了王皓、毕雯珺、贾冰、牛莉等实力派演员的加盟情况。
• 在文章的结尾，再次呼吁观众走进影院观看电影。

此外，我还对文章的语言进行了一些润色，使其更加简洁明了，表达更加准确。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.